Literature DB >> 2676655

Pathogenesis of diabetic retinopathy.

R L Engerman1.   

Abstract

Diabetic retinopathy involves anatomic changes in retinal vessels and neuroglia. The pathogenetic mechanism responsible for retinopathy is imperfectly understood, but much of the mechanism is apparently reproduced by experimental diabetes in animals and by chronic elevation of blood galactose in nondiabetic animals. The evidence that retinopathy is a consequence of excessive blood sugars and their sequelae is consistent with a demonstrated inhibition of retinopathy by strict glycemic control in diabetic dogs. However, retinopathy in the dog model has shown a tendency to resist intervention by strict control. Biochemical and pathophysiological sequelae of hyperglycemia possibly critical to the development of retinopathy in humans and animal models are being studied in many laboratories. Retinopathy occurs in experimental galactosemia in the absence of the renal hypertrophy, mesangial expansion, and glomerular obliteration typical of diabetes in humans and dogs, implying that retinopathy and nephropathy differ appreciably in pathogenesis.

Entities:  

Mesh:

Year:  1989        PMID: 2676655     DOI: 10.2337/diab.38.10.1203

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  73 in total

1.  Sphingosine 1-phosphate receptor regulation of N-cadherin mediates vascular stabilization.

Authors:  Ji-Hye Paik; Athanasia Skoura; Sung-Suk Chae; Ann E Cowan; David K Han; Richard L Proia; Timothy Hla
Journal:  Genes Dev       Date:  2004-09-15       Impact factor: 11.361

2.  Bax is increased in the retina of diabetic subjects and is associated with pericyte apoptosis in vivo and in vitro.

Authors:  F Podestà; G Romeo; W H Liu; S Krajewski; J C Reed; C Gerhardinger; M Lorenzi
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

3.  A study of capillary pericyte viability on extracellular matrix produced by endothelial cells in high glucose.

Authors:  E Beltramo; S Buttiglieri; F Pomero; A Allione; F D'Alù; E Ponte; M Porta
Journal:  Diabetologia       Date:  2003-02-26       Impact factor: 10.122

4.  Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy.

Authors:  Maria Enge; Mattias Bjarnegård; Holger Gerhardt; Erika Gustafsson; Mattias Kalén; Noomi Asker; Hans-Peter Hammes; Moshe Shani; Reinhardt Fässler; Christer Betsholtz
Journal:  EMBO J       Date:  2002-08-15       Impact factor: 11.598

5.  Retinal microangiopathy in a mouse model of inducible mural cell loss.

Authors:  Cammi N Valdez; Joseph F Arboleda-Velasquez; Dhanesh S Amarnani; Leo A Kim; Patricia A D'Amore
Journal:  Am J Pathol       Date:  2014-08-01       Impact factor: 4.307

6.  Increased synthesis of leukotrienes in the mouse model of diabetic retinopathy.

Authors:  Ramaprasad Talahalli; Simona Zarini; Nader Sheibani; Robert C Murphy; Rose A Gubitosi-Klug
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-15       Impact factor: 4.799

7.  5-Lipoxygenase, but not 12/15-lipoxygenase, contributes to degeneration of retinal capillaries in a mouse model of diabetic retinopathy.

Authors:  Rose A Gubitosi-Klug; Ramaprasad Talahalli; Yunpeng Du; Jerry L Nadler; Timothy S Kern
Journal:  Diabetes       Date:  2008-03-17       Impact factor: 9.461

8.  Delivery of antioxidant enzyme genes to protect against ischemia/reperfusion-induced injury to retinal microvasculature.

Authors:  Baihua Chen; Sergio Caballero; Soojung Seo; Maria B Grant; Alfred S Lewin
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-07-23       Impact factor: 4.799

9.  High Glucose and Glucose Deprivation Modulate Müller Cell Viability and VEGF Secretion.

Authors:  S Vellanki; A Ferrigno; Y Alanis; B S Betts-Obregon; A T Tsin
Journal:  Int J Ophthalmol Eye Sci       Date:  2016-02-15

10.  Methylglyoxal induces apoptosis mediated by reactive oxygen species in bovine retinal pericytes.

Authors:  Jaetaek Kim; Jang-Won Son; Jeong-An Lee; Yeon-Sahng Oh; Soon-Hyun Shinn
Journal:  J Korean Med Sci       Date:  2004-02       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.